Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
Renale Effekte und Sicherheit von Tirzepatid bei Personen mit und ohne Diabetes: systematische Übersicht und Metaanalyse
World Journal of Diabetes · 15.02.2025 · 16 (2)
DOI: 10.4239/wjd.v16.i2.101282 ↗Auf einen Blick
15 RCTs zeigen unter Tirzepatid eine stärkere Senkung der UACR als unter Kontrollen. Für eGFR ergaben sich keine nachteiligen Effekte, die renale Sicherheit war günstig.
Fragestellung
Welche renalen Vorteile und welche Sicherheit hat Tirzepatid im Vergleich zu Kontrollen bei Personen mit und ohne Diabetes?
Methode
Systematische Übersicht und Metaanalyse von RCTs; random-effects-Modelle; Vergleich mit Placebo oder aktivem Komparator.
Ergebnisse
15 RCTs mit n = 14471. UACR sank über 26-72 Wochen unter 10 mg (MD -26.95% [-40.13, -13.76]) und 15 mg (MD -18.03% [-28.58, -7.47]) stärker als unter Placebo. eGFR war vergleichbar; keine Zunahme renaler Unerwünschter Ereignisse.
Einschränkungen
Kurzzeitdaten aus RCTs; größere RCTs sind erforderlich, um längerfristige renale Vorteile zu belegen.
Schlussfolgerung der Autor:innen
Kurzzeitdaten aus RCTs mit niedrigem RoB sprechen dafür, dass Tirzepatid UACR günstig beeinflusst, ohne eGFR nachteilig zu verändern; die renale Sicherheit ist beruhigend.
Kernaussagen
- Tirzepatid senkte die UACR stärker als Placebo und Insulin.
- Keine nachteiligen Effekte auf eGFR beobachtet.
- Keine Zunahme renaler Unerwünschter Ereignisse berichtet.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift World Journal of Diabetes, online erschienen am 15.02.2025. Verfasst von Abm Kamrul-Hasan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Dhaka, Bangladesh. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND Type 2 diabetes (T2D), as well as obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The renal impacts of glucose-lowering and weight-lowering drugs and their potential benefits in preventing CKD often guide clinicians in choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available on the renal effects and safety profile of tirzepatide. AIM To explore the renal benefits and safety of tirzepatide vs controls. METHODS RCTs involving patients receiving tirzepatide for any indication in the intervention arm and placebo or active comparator in the control arm were searched through multiple electronic databases. The co-primary outcomes were percent change from baseline (CFB) in urine albumin-to-creatinine ratio (UACR) and absolute CFB in estimated glomerular filtration rate (eGFR; in mL/min/1.73 m2); the secondary outcome was tirzepatide’s renal safety profile. RevMan web was used to conduct meta-analysis using random-effects models. Outcomes were presented as mean differences (MD) or risk ratios with 95% confidence intervals. RESULTS Fifteen RCTs (n = 14471) with mostly low risk of bias (RoB) were included. Over 26-72 weeks, tirzepatide 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] and 15 mg [MD -18.03% (-28.58, -7.47), P = 0.0008] were superior to placebo in percent reductions of UACR. Tirzepatide, at all doses, outperformed insulin in percent reductions of UACR. Compared to the placebo, the percent UACR reduction was greater in subjects with T2D than those with obesity but without T2D (MD -33.25% vs -7.93%; P = 0.001). The CFB in eGFR with all doses of tirzepatide was comparable [5 mg: MD- 0.36 (-1.41, 2.14); 10 mg: MD- 1.17 (-0.22, 2.56); 15 mg: MD- 1.42 (-0.04, 2.88)]; P < 0.05 for all] vs insulin. Tirzepatide (pooled and separate doses) did not increase the risks of adverse renal events, urinary tract infection, nephrolithiasis, acute kidney injury, and renal cancer compared to the placebo, insulin, and glucagon-like peptide-1 receptor agonists. CONCLUSION Short-term data from RCTs with low RoB suggests that tirzepatide positively impacts UACR without detrimental effects on eGFR in subjects with T2D and obesity without T2D, with a reassuring renal safety profile. Larger RCTs are warranted to prove the longer-term renal benefits of tirzepatide, which might also prevent eGFR decline and worsening of CKD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Dhaka, Bangladesh.
- Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Nagpur, Nagpur 441108, Maharashtra, India.
- Department of Endocrinology, CEDAR Superspeciality Clinics, Dwarka, New Delhi 110075, India.
- Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education & Research, Mysore 570015, India.
- Department of Urology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh.
- Department of Endocrinology, Clinical Centre of Montenegro, Podgorica 81000, Montenegro.
Zitieren
APA
Kamrul-Hasan, A., Patra, S., Dutta, D., Nagendra, L., Muntahi-Reza, A., Borozan, S., & Pappachan, J. M. (2025). Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis. World Journal of Diabetes, 16(2). https://doi.org/10.4239/wjd.v16.i2.101282
Vancouver
Kamrul-Hasan A, Patra S, Dutta D, Nagendra L, Muntahi-Reza A, Borozan S, et al. Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis. World Journal of Diabetes. 2025;16(2). doi:10.4239/wjd.v16.i2.101282
BibTeX
@article{KamrulHasan2025,
author = {Kamrul-Hasan, Abm and Patra, Shinjan and Dutta, Deep and Nagendra, Lakshmi and Muntahi-Reza, Afm and Borozan, Sanja and Pappachan, Joseph M},
title = {Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis},
journal = {World Journal of Diabetes},
year = {2025},
volume = {16},
number = {2},
doi = {10.4239/wjd.v16.i2.101282}
}
EUVIMED